Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer? Bernard BannwarthMarie Kostine Current Opinion 28 June 2017 Pages: 1377 - 1387
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook Jusleen AhluwaliaJeremy UdkoffLawrence F. Eichenfield Leading Article 05 July 2017 Pages: 1389 - 1397
Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects Garyphallia PoulakouDimitrios K. MatthaiouGeorge Dimopoulos Therapy in Practice 24 July 2017 Pages: 1399 - 1412
Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity Andrea SantamatoFrancesco Panza Review Article 19 July 2017 Pages: 1413 - 1422
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review Selene R. T. VeermanPeter F. J. SchulteLieuwe de Haan Review Article 03 August 2017 Pages: 1423 - 1459
Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases Y. SchullerC. E. M. HollakM. Biegstraaten Original Research Article Open access 27 July 2017 Pages: 1461 - 1472
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT Yahiya Y. Syed Adis Drug Evaluation 08 August 2017 Pages: 1473 - 1480
Delafloxacin: First Global Approval Anthony Markham AdisInsight Report Open access 26 July 2017 Pages: 1481 - 1486
Guselkumab: First Global Approval Anthony Markham AdisInsight Report 17 August 2017 Pages: 1487 - 1492